DSM-Firmenich Q3 2026 sales top €2.3bn as EBITDA rises

By Sophie Lindqvist

DSM-Firmenich reported more than €2.3bn in third-quarter 2026 sales, while adjusted EBITDA rose 8% like-for-like to €482m from €458m. Management attributed the increase to volume-led growth in perfumery and beauty.

Where did growth come from?

DSM-Firmenich said ongoing innovation across its beauty portfolio helped sustain sales during the quarter. CEO Dimitri de Vreeze said: “We delivered another good quarter of volume-led growth and continued adjusted EBITDA margin improvement.”

He said all businesses contributed well and linked that breadth to portfolio quality in a highly dynamic global macroeconomic environment. The statement offered no individual market, customer or product attribution for that breadth.

• Fine fragrances maintained strong momentum, delivering high single-digit like-for-like growth, with particular strength in prestige fine-fragrance markets.
• Consumer fragrances delivered double-digit like-for-like growth, which DSM-Firmenich attributed to innovation and reformulations.
• Ingredients achieved mid-single-digit growth.

The disclosed rates establish direction, not each segment’s contribution. DSM-Firmenich gave no segment sales values, so the faster fragrance rates do not prove that fragrances generated the largest absolute increase. What the data do show is that both reported fragrance categories grew faster than the ingredients business.

The practical result is broad growth, with fragrance outpacing ingredients and no segment values disclosed.

What does the result mean for formulators and buyers?

DSM-Firmenich named no individual INCI names, concentrations, reformulated formulas or product launch dates. For formulators, compliance teams and purchasers, the result establishes company-level momentum, not a basis for shortlisting or approving a specific ingredient. Any adoption decision still depends on product-level technical and regulatory files, which this update does not provide.

Management’s use of volume-led also narrows what buyers can infer. The release identifies sales volume as the principal growth driver, but it provides no price-and-volume bridge, customer breakdown or segment margin, and it does not establish that pricing strengthened. Buyers should therefore separate broader demand for DSM-Firmenich’s output from conclusions about pricing.

For commercial teams, the evidence points to three active routes: ongoing beauty innovation, consumer-fragrance reformulation and ingredient sales. The update does not identify the products behind that innovation or the markets driving them beyond the prestige fine-fragrance reference. That leaves product-level follow-up essential for teams mapping the pipeline to formulation briefs or procurement plans.

What should buyers watch next?

De Vreeze said: “Moving into the fourth quarter, business conditions remain supportive, with a healthy innovation pipeline, high win rates and continued good sales growth.” The company supplied no Q4 sales target and did not quantify pipeline value, win-rate percentages or the adjusted EBITDA margin improvement cited earlier.

Management said it remained on track to deliver its 2026 targets through top-line growth and margin expansion, while maintaining a strong focus on cash and capital discipline.

Its cost savings and restructuring programme is progressing well, according to the company.

Management framed current performance and savings as a platform for delivering the 2027/2028 targets, although it gave no numerical targets for either year.

The forward language remains qualitative. Neither healthy nor high win rates identifies project volume, commercial value, lead times or customer conversion, so those terms cannot support a procurement forecast without further disclosure. Q4 sales and margin delivery will provide the first direct test of whether management’s stated momentum continues.

On 9 February 2026, DSM-Firmenich announced its intention to divest its Animal Nutrition & Health business to CVC Capital Partners for an estimated €2.2bn. The company framed the move as doubling down on its nutrition, health and beauty offering.

Because the announcement concerns an intention rather than a completed sale, the update gave no closing date, transaction conditions or detail on contracts, supply arrangements and product lines that might move with the business. For beauty procurement, the release does not yet define any supply-continuity implications.

The next checkpoints are Q4 2026 sales, the margin delivery behind the 8% EBITDA increase, conversion of the stated innovation pipeline and high win rates, and progress toward the 2027/2028 targets; the €2.2bn divestment remained an announced intention in the information provided.